Recent Advances in Design of Glycogen Phosphorylase Inhibitors

Author(s): Li Wen-Liang, Chen Jian, Luo Mei-Hong, Lu Han, Ma Li, Li Wei-Lin

Journal Name: Current Enzyme Inhibition

Volume 7 , Issue 4 , 2011

Become EABM
Become Reviewer
Call for Editor


Glycogen phosphorylase (GP) has been firmly proved as an important target for treatment of type 2 diabetes. With the rapid increase of type 2 diabetic patients recently, it is becoming an interesting field to discover GP inhibitor for potential antidiabetic drugs. As GP is a typical allosteric protein with several key inhibitor binding sites including the inhibitor, the catalytic, the allosteric and the new allosteric sites, the research works were mainly focused on compounds that can bind these sites and show selective inhibitory effect. This paper mainly reviewed the advances in the design of inhibitors for different binding sites of GP and aimed at providing readers with some useful hints towards more effective GP inhibitors.

Keywords: Glycogen phosphorylase, inhibitors, binding sites, type 2 diabetes, allosteric protein, metabolism, gluconeogenesis, cyclodextrins, van der Waals bonds, riboflavin

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Published on: 04 April, 2012
Page: [259 - 267]
Pages: 9
DOI: 10.2174/157340811799860533
Price: $65

Article Metrics

PDF: 8